Peel Hunt

Shield Therapeutics is an independent specialty pharmaceutical company based in Wollerau, Switzerland, concentrating on the development and commercialization of late-stage, mineral-derived pharmaceuticals aimed at addressing significant unmet medical needs. The company’s primary focus is on its lead product, Feraccru, which is designed for the treatment of iron deficiency anemia associated with inflammatory bowel disease, as well as chronic kidney disease. Additionally, Shield Therapeutics is advancing PT20, a product intended for the management of hyperphosphatemia, which is nearing the final stages of development. The company generates most of its revenue from the Feraccru segment.

Britishvolt is a battery technology developer focused on manufacturing low-carbon batteries to support the electrification of society. The company collaborates with strategic partners and suppliers to enhance its offerings, utilizing quality manufacturing processes, advanced modeling techniques, and recycled materials. Britishvolt aims to accelerate sustainable transport and contribute to the renewable energy sector, positioning itself as a key player in the transition towards a more electrified future.